Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 200032, China
Location status: Recruiting
NCT Number: NCT07601087
The purpose of this Phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-7156 in healthy participants.
Interested in participating?
Request Info18 year–55 year
All sexes
Interventional
Phase 1
Shanghai, Shanghai Municipality, 200032, China
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HRS-7156, specified dose on specified day.
HRS-7156 placebo, specified dose on specified day.
Time frame: Up to 14 days.
Safety: Incidence of adverse event (AE) and serious adverse event (SAE).
Time frame: Day 1 - Day 9.
Pharmacokinetics (PK) parameter of HRS-7156.
Time frame: Day 1 - Day 9.
Pharmacokinetics (PK) parameter of HRS-7156.
Time frame: Day 1 - Day 9.
Pharmacokinetics (PK) parameter of HRS-7156.
Time frame: Day 1 - Day 2.
Pharmacokinetics (PK) parameter of HRS-7156.
Time frame: Day 1 - Day 9.
Pharmacodynamics (PD) endpoint of HRS-7156.
Contact information is provided by the study sponsor or research team.
Kaiyun Zhang
CONTACT
Sheng Qi
CONTACT
Shandong Suncadia Medicine Co., Ltd.
Industry
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Oral Doses of HRS-7156 in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05753059
Cardiovascular Diseases, Heart Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT06935370
Cardiovascular Diseases, Heart Diseases
Beverly Hills, California, United States
View Trial DetailsNCT07232030
Cardiovascular Diseases, Heart Diseases
Mobile, Alabama, United States
View Trial DetailsNCT07666698
Cardiovascular Diseases, Heart Diseases
Nanjing, Jiangsu, China
View Trial Details